Medinotec Inc. (MDNC) stock intrinsic value fair value estimate & owner earnings analysis

Medinotec runs a small medical-device business out of Johannesburg, South Africa. It makes its own products (the Trachealator airway balloon, the Outflo aortic valve dilation catheter and the Cape Cross PTCA balloons) and, far more importantly, distributes cardiology and renal dialysis products made by other companies. In the year to February 2026, revenue was $9.7 million, of which $8.1 million came from distribution agreements in South Africa and only $0.6 million from the United States. About 89% of all revenue came from one customer, DISA Life Sciences, a South African sub-distributor that is linked to the company's founder and CEO. That concentration is the single most important fact about this business. How we measured earnings. We start from the cash the business generates, remove timing swings in receivables, inventory and payables, subtract share-based pay, and deduct only the capital spending needed to stay in place (very little here). Two accounting points mattered. First, taxes: the company accrued far more income tax than it paid in cash in each of the last two years because DISA Life Sciences settled some of those liabilities by netting them against what it owed the company, so we treated the unpaid tax as a real cost. Second, in fiscal 2026 the reported operating cash flow of $0.9 million is flattered by the same kind of netting: DISA Life Sciences paid off roughly $0.98 million owed to another company owned by the CEO in exchange for a matching reduction in its own receivable. We built earnings from the profit side rather than from receivable movements. On that basis owner earnings were $2.3 million ($0.20 per share) in fiscal 2025 and $0.77 million ($0.065 per share) in fiscal 2026, and the company now carries essentially no debt. We used fiscal 2026 as the level that describes the business today, because the sharp drop from fiscal 2025 was structural: selling costs jumped from $0.11 million to $1.49 million, of which $1.32 million is reimbursement to the South African distributor for its sales force, and general and administrative costs rose by $0.97 million, including about $0.55 million of executive pay now routed through outside entities. Those costs are running now, and the first quarter of fiscal 2027 (net income of $0.22 million on revenue of $2.65 million) sits at roughly the fiscal 2026 run-rate, not the fiscal 2025 one. Fiscal 2025 was lifted by a cost structure that has since changed, so it was left out of the anchor. Adding back the $88 thousand of interest paid on the now-repaid related-party loan, the business generated about $0.073 per share of cash before lenders. Growth. Owner earnings fell about 67% in the latest year, so we assume no growth in year 1 and none afterwards. We give no credit for United States expansion of the Trachealator and Outflo (Outflo received FDA clearance in March 2025 but U.S. sales actually declined in fiscal 2026), for the three products in early development, or for the 24% revenue increase in the latest quarter, because one quarter is not a demonstrated trend. The only thing credited is that the existing South African distribution relationships keep producing what they produced last year: the cardiology distribution has been in place for at least three years and the renal dialysis agreement began in the third quarter of fiscal 2025. The filing does not disclose how long these agreements run. Base case: the fiscal 2026 level of about $0.073 per share of business cash flow holds for ten years, then fades to zero over the following ten years because nothing in the filings shows the distribution rights lasting beyond that. That is worth about $0.69 per share, and the company owes essentially nothing. We also count about $1.0 million (about $0.085 per share) of the $2.76 million in cash as surplus; the rest is needed to run the business. Base value is about $0.77 per share. Bear case: the cost pressure already disclosed continues, with distributor support costs and executive pay growing and U.S. sales and margins on the company's own products continuing to shrink, so cash flow settles at roughly 55% of the fiscal 2026 level ($0.04 per share) for five years. After that, the third-party distribution rights are not renewed and the business runs off over five years. The risks named in the filings are the 89% dependence on one related-party customer, the fact that one European supplier represents 53% of payables, and South African exchange controls that can delay moving cash to the United States. That is worth about $0.22 per share, plus $0.085 of surplus cash, or about $0.31 per share. There is no debt to add to the shortfall in any case. Bull case: the business's own levers deliver. The first full year of dialysis distribution and the first-quarter improvement carry through, and cash flow rises to about $0.11 per share and holds ten years before fading over the next ten. That is worth about $1.03 per share plus $0.085 of surplus cash, or about $1.12 per share. What could make this wrong. The largest risk is a change in terms with DISA Life Sciences or the third-party suppliers, since the agreements are with a related party and their duration is not disclosed. The cost increases of fiscal 2026 could also prove larger or smaller than we assume. Reported cash flow is hard to interpret because of the related-party set-offs, so we relied on profit-based measures. The shares are quoted on the OTCQX with no liquid market, so trades at a fair value may be difficult to complete.